智通财经APP讯，中国生物制药(01177)公布，集团开发的"TQC3721 (PDE3/4抑制剂)"、"TQC2731 (TSLP单抗)"、"TQC3403 (乌美溴铵维兰特罗吸入粉雾剂)"将于9月27日至10月1日举行的2025年欧洲呼 吸学会年会 (ERS 2025)公布4项研究成果。 ...

「TQC3721 (PDE3/4抑制劑）」、「TQC2731 (TSLP單抗）」、「TQC3403 (烏美溴銨維蘭 特羅吸入粉霧劑)」共4項研究數據在ERS 2025公布 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團開 發的「TQC3721 (PDE3/4抑制劑）」、「TQC2731 (TSLP單抗）」、「TQC3403 (烏美溴銨維蘭特羅吸入粉 霧劑)」將於9月27日至10月1日舉行的2025年歐洲呼吸學會年會 (ERS 2025）公布4項研究成果。 TQC3721 (PDE3/4抑制劑） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQC2731 (TSLP單抗） TQC3721是一款全新機制的吸入性PDE3/4抑制劑，具有擴張支氣管和抗炎的雙重作用，從而減 輕患者症狀並抑制炎 ...

Core Insights - The pharmaceutical industry is witnessing a significant transformation towards innovation, with many companies reporting that innovative drugs now account for over half of their revenues [1] Group 1: Company Performance - Heng Rui Medicine reported a revenue of 15.762 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, with net profit reaching 4.45 billion yuan, up 29.67% [2] - Heng Rui's innovative drug sales and licensing income amounted to 9.561 billion yuan, representing 60.66% of total revenue, with innovative drug sales reaching 7.570 billion yuan [2] - Han Sen Pharmaceutical achieved approximately 6.145 billion yuan in innovative drug and cooperative product sales, a year-on-year increase of 22.1%, accounting for about 82.7% of total revenue [3] - Han Sen's total revenue for the first half of 2025 was 7.434 billion yuan, up 14.3%, with net profit of 3.135 billion yuan, a 15% increase [4] - Yuan Da Pharmaceutical reported a record revenue of approximately 6.11 billion HKD, with innovative and barrier products accounting for about 51% of total revenue, a nearly 15 percentage point increase year-on-year [4] - Xian Sheng Pharmaceutical's total revenue grew by 15.1% to 3.585 billion yuan, with adjusted net profit of 651 million yuan, up 21.1%, driven by innovative drug revenue [4] Group 2: R&D Investment - Heng Rui Medicine invested 3.871 billion yuan in R&D in the first half of 2025, with cumulative R&D investment exceeding 48 billion yuan [5] - Xian Sheng Pharmaceutical reported an R&D investment rate of 28.7%, with cumulative R&D investment exceeding 10 billion yuan over the past decade [5] Group 3: Market Expansion and Challenges - China National Pharmaceutical's innovative drug revenue accounted for 44.4% of total revenue, with plans to enhance its innovative drug business through acquisitions, including a recent acquisition of a Shanghai-based innovative drug company for 500 million USD [6] - Despite the growth in innovative drug sales, most companies are still primarily focused on the domestic market, with limited international presence [6][7] - Heng Rui has established 15 external licensing collaborations and is actively seeking partnerships with global pharmaceutical companies to enhance international market penetration [8] - Xian Sheng Pharmaceutical is accelerating its global layout, having achieved three self-researched products going overseas, with external licensing expected to be a sustainable growth source [8]

Investment Rating - The report maintains an "Overweight" rating for the industry, indicating a positive outlook for the sector over the next 6 to 12 months [5][42]. Core Insights - The innovative pharmaceutical and medical device sectors are experiencing significant growth, with several leading companies reporting positive earnings for the first half of the year. The report emphasizes a strong belief in the investment potential of innovative drugs, particularly in international markets [6][13]. - The report highlights that the overall pharmaceutical sector has shown resilience, with a year-to-date return of 26.33%, outperforming the Shanghai Composite Index by 15.07 percentage points [18]. - Key segments within the pharmaceutical industry, such as traditional Chinese medicine, medical devices, and biological products, have shown positive growth trends, with respective increases of 2.86%, 2.37%, and 2.22% [6][18]. Summary by Sections Industry Overview - The report notes that the pharmaceutical industry comprises 494 listed companies with a total market capitalization of approximately 76,735.11 billion [2]. - The report indicates that the innovative drug sector is the main driver of market activity, with significant developments in clinical trials for several domestic innovative drugs [6][13]. Market Performance - The report details that the Shanghai Composite Index rose by 4.18% while the pharmaceutical sector increased by 1.05%, ranking 29th among 31 sub-industries [6][18]. - The report provides a breakdown of sub-sector performance, with traditional Chinese medicine and medical devices leading the gains [6][18]. Key Recommendations - The report suggests focusing on specific segments with potential catalysts, including second-generation immune-oncology drugs, GLP-1 drugs, and small nucleic acid therapies [8][13]. - It recommends monitoring companies involved in innovative medical devices and high-demand consumables, as well as CRO/CDMO firms that support the pharmaceutical supply chain [8][13]. Company Performance - The report highlights several companies with strong earnings growth, including 35.85 billion in revenue for a leading company, reflecting a 15.14% year-on-year increase [31]. - It also notes significant foreign investment in domestic innovative drug companies, indicating growing international recognition of their capabilities [7][13].

Group 1 - The Hang Seng Innovation Drug ETF (159316) has shown active trading with a turnover of 31.05% and a transaction volume of 499 million yuan as of August 25, 2025, indicating a strong market interest [1] - As of August 22, 2025, the latest scale of the Hang Seng Innovation Drug ETF reached 1.598 billion yuan, marking a new high since its inception [1] - In the past five trading days, the Hang Seng Innovation Drug ETF experienced net inflows on four occasions, totaling 330 million yuan [1] Group 2 - The Hang Seng Innovation Drug ETF closely tracks the Hang Seng Innovation Drug Index, which reflects the performance of Hong Kong-listed companies involved in the research, development, and production of innovative drugs [2] - The Hang Seng Hong Kong Stock Connect Innovation Drug Index (HSSCIHKI) is the only "100% purity" innovative drug index in the market, focusing on companies holding core patents and directly participating in innovative drug R&D and commercialization [2] - The Hang Seng Innovation Drug ETF (159316) is currently the only ETF product tracking the Hang Seng Innovation Drug Index, providing high elasticity and scarcity, thus helping investors seize the investment opportunities in the Hong Kong innovative drug sector [2] Group 3 - Domestic large pharmaceutical companies have stabilized their generic drug business after the impact of centralized procurement, and the results of their innovative transformation are significant [1] - Since 2025, Heng Rui Medicine has disclosed three BD collaborations with a total upfront payment of approximately 720 million USD, with potential total transaction amounts exceeding 13.7 billion USD, indicating that BD could become a sustainable income source [1] - China Biopharmaceutical announced in June that it would achieve a "landmark heavyweight external authorization transaction," and in July, it fully acquired Li Xin Pharmaceutical for a net amount of 500 million USD, enhancing its dual antibody/ADC platform and international R&D capabilities [1] - Recently, Heng Rui Medicine plans to repurchase up to 2 billion yuan, while Sheng Sen Pharmaceutical intends to repurchase up to 500 million yuan, demonstrating companies' confidence in future development through intensive buybacks and increases [1]

Group 1 - The core viewpoint indicates that domestic large pharmaceutical companies in China have stabilized their revenue from generic drugs after initial disruptions from centralized procurement, and the results of innovation transformation are becoming evident [1] - Heng Rui Medicine has disclosed three business development (BD) collaborations this year with multinational pharmaceutical companies such as Merck, GSK, and others, with a total upfront payment of approximately $720 million and a potential total transaction value exceeding $13.7 billion, suggesting BD could become a sustainable revenue source for the company [1] - China National Pharmaceutical Group is expected to achieve a "landmark external authorization deal" involving potential products by June this year, and in July, it realized a net gain of $500 million by acquiring core assets and continuing BD collaboration, enhancing its dual antibody/ADC platform and international R&D capabilities [1] Group 2 - From a fundamental perspective, innovative drugs are currently the most clearly defined industry trend within the pharmaceutical sector, with significant growth potential, and innovative drugs are expected to remain the main investment theme throughout the year [1] - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech, with a 20% limit on daily price fluctuations to better align with sector volatility [1] Group 3 - Since the "924 market" began, the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovation drug indices, with returns of 75%, 70%, and 70% for the Sci-Tech Innovation Drug, Hong Kong Innovation Drug, and Hang Seng Hong Kong Stock Connect Innovation Drug indices, respectively, during the market rebound from September 24, 2024, to June 30, 2025 [2]

Investment Rating - The industry rating is "Outperform the Market" [4] Core Insights - The domestic Big Pharma companies have shown impressive mid-year performance, with significant contributions from innovative drug businesses driving revenue growth [2] - The report highlights the successful transformation of traditional pharmaceutical companies towards innovation, with overseas collaboration and licensing deals enhancing their financial performance [2] - The report emphasizes the importance of the biopharmaceutical industry as a strategic emerging industry, with government support for high-quality technological supply and policy backing [2] Summary by Sections Industry Performance - The SW Pharmaceutical and Biotech Index increased by 1.05%, underperforming the CSI 300 Index which rose by 4.18% during the week [2] - Medical device and vaccine sectors showed relative gains, while CXO sector experienced a decline of 3.00% [2] Company Highlights - Heng Rui Medicine reported a revenue of 15.761 billion yuan, a year-on-year increase of 15.88%, with innovative drug sales contributing 7.570 billion yuan, accounting for 54.97% of product sales [2] - China Biopharmaceutical achieved a revenue of 17.575 billion yuan, a 10.71% increase, with innovative drugs contributing 7.800 billion yuan, a growth of 27.2% [2] Policy and Market Trends - The approval of the Jiangsu Free Trade Zone biopharmaceutical development plan aims to create a globally influential biopharmaceutical industry cluster [2] - The report suggests that the positioning of the pharmaceutical industry has evolved from a "livelihood project" to a "new productive force," highlighting the significance of innovative drug exports [2] Investment Strategy - The report identifies three main investment themes: 1. Focus on innovative drug exports, particularly in ADC, PD-1 bispecific antibodies, and weight-loss drugs [2] 2. High-growth CXO sector leaders [2] 3. Revaluation of Big Pharma pipelines [2] - The report maintains a bullish outlook on the pharmaceutical technology market for the year, emphasizing the importance of upcoming academic conferences and national health insurance negotiations [2]

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [31]. Core Insights - The report highlights the emergence of innovative drugs, particularly focusing on PD-1 (PD-L1)/VEGF dual antibodies, with significant clinical data being presented at the 2025 World Lung Cancer Conference [4]. - The report emphasizes the continuous growth potential in the innovative drug sector, suggesting that companies with rich pipelines and strong single-product potential should be closely monitored [6]. Summary by Sections Industry Overview - The report summarizes ongoing clinical trials for PD-L1 (PD-1)/VEGF-A dual antibodies in China, detailing various drugs, their developers, clinical stages, and results [4]. - Key drugs include: - Ivosidenib, approved for non-squamous non-small cell lung cancer, showing a median progression-free survival (mPFS) of 7.06 months compared to 4.80 months [4]. - SSGJ-707, currently in Phase III, demonstrating an overall response rate (ORR) of 58.3% [4]. - PM8002, also in Phase III, achieving an unconfirmed ORR of 86.8% in extensive-stage small cell lung cancer [4]. Investment Strategy - The report recommends focusing on companies with diverse pipelines such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group [6]. - It also suggests monitoring companies with high single-product potential like Yipinhong, 3SBio, and Kangzhe Pharmaceutical, as well as those with leading technology platforms like Dongcheng Pharmaceutical and Kelun-Biotech [6]. Market Performance - The A-share pharmaceutical sector increased by 1.05% last week, while the Shanghai and Shenzhen 300 Index rose by 4.18%, ranking the pharmaceutical industry 26th among 28 sectors [9][20]. - The Hong Kong pharmaceutical sector saw a 0.93% increase, outperforming the Hang Seng Index, which rose by 0.69%, ranking 8th among 11 sectors [30].

Core Viewpoint - The report from China Merchants Securities International indicates that China's biopharmaceutical sector experienced a 10% year-on-year revenue increase in the first half, reaching 17.6 billion yuan, exceeding expectations [1] Group 1: Company Performance - The management guidance suggests an acceleration in growth for the second half of the year, with projections indicating a return to double-digit growth in 2026 and 2027 [1] - The growth potential in the respiratory and liver disease sectors is considered underestimated by the market, as the company possesses superior growth prospects and abundant business development opportunities [1] Group 2: Market Position and Strategy - The firm maintains an optimistic outlook on China National Pharmaceutical Group, viewing it as a market leader benefiting from strong performance in oncology, surgical, and analgesic drugs [1] - The impact of centralized procurement policies on average prices is expected to stabilize, reducing negative effects [1] - The company has effectively refocused on four major therapeutic areas through asset disposals, which is anticipated to enhance overall operational efficiency and quality [1] Group 3: Target Price and Rating - The target price for the company has been raised to 9.8 Hong Kong dollars, with a maintained "Buy" rating [1]

Core Viewpoint - China Biopharmaceutical's revenue for the first half of the year increased by 10% year-on-year, reaching 17.6 billion yuan, exceeding expectations [1] Group 1: Financial Performance - The management guidance indicates an acceleration in growth for the second half of the year [1] - The firm expects the company to return to double-digit growth in 2026 and 2027 [1] Group 2: Market Potential - The growth potential in the respiratory and liver disease sectors is considered underestimated by the market [1] - The company is viewed as having superior growth prospects and abundant business development opportunities [1] Group 3: Investment Rating - The target price for the company has been raised to 9.8 HKD, maintaining a "Buy" rating [1] - The firm holds an optimistic view on China Biopharmaceutical, benefiting from strong performance in oncology, surgical, and analgesic drugs [1] Group 4: Strategic Focus - The company has effectively disposed of assets to refocus on four major therapeutic areas [1] - This strategic refocus is expected to enhance overall operational efficiency and quality [1]